Mirum Pharmaceuticals, Inc. has reported a significant milestone with its investigational drug, brelovitug. The company announced on November 10, 2026, that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). This development is crucial as it forms part of the basis for the company's U.S. registration package for the drug.

The AZURE-4 study is the second of two Phase 3 studies designed to assess the efficacy of brelovitug. The results are expected to enhance Mirum's position in the pharmaceutical preparations industry, particularly in the hepatitis treatment market.

Background

Mirum Pharmaceuticals, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC: 2834). The company trades under the ticker symbol MIRM on the Nasdaq exchange. Mirum focuses on developing innovative therapies for patients with rare diseases, particularly those related to liver health.

What the Filing Says

According to the filing, "On November 10, 2026, Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug." The study involved 113 treatment-naïve patients and demonstrated significant efficacy, with 59% of patients receiving 300 mg of brelovitug achieving the combined endpoint of virologic response and ALT normalization.

Impact

This announcement may significantly affect patients suffering from chronic hepatitis delta virus, offering them a potential new treatment option. Additionally, it positions Mirum Pharmaceuticals favorably against competitors in the pharmaceutical preparations industry, particularly those focusing on liver diseases.

What's Next

The filing does not specify what happens next, but it is anticipated that Mirum will continue to prepare for the submission of its U.S. registration package for brelovitug.